Abstract
The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Volume: 4 Issue: 3
Author(s): Kevin Kimbro and Sabrenia Parker
Affiliation:
Keywords: Toll-like receptors, cancer, innate immunity, immunology
Abstract: The first lines of defense in the human innate immune system are membrane receptors called Toll-like receptors (TLRs). This family of receptors functions as primary sensors to recognize microbial pathogens. Subsequent binding of ligands to TLRs lend to the activation of cellular signaling pathways that regulate expression of genes related to inflammation and immunity. The discovery and supporting evidence of functional and structural diversity suggests TLRs are key participants in cellular immunity and are important to various medical conditions including the tumor microenvironment. TLR heterogeneity emphasizes the role of these receptors and suggests a new opportunity to develop therapies targeting specific or multiple TLRs that may contribute to the treatment of a myriad of diseases including various cancers. In this article, we intend to focus on a number of recently issued patents related to TLRs and to propose the relevance of these patents to novel treatments for cancers.
Export Options
About this article
Cite this article as:
Kimbro Kevin and Parker Sabrenia, Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206904
DOI https://dx.doi.org/10.2174/157489209789206904 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytosterols in Physiological Concentrations Target Multidrug Resistant Cancer Cells
Medicinal Chemistry Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry The PP2A-Aβ Gene is Regulated by Multiple Transcriptional Factors Including Ets-1, SP1/SP3, and RXRα /β
Current Molecular Medicine Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Regulation of Foxo-Dependent Transcription by Post-Translational Modifications
Current Drug Targets Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry Physiological Functions of NO-Sensitive Guanylyl Cyclase Isoforms
Current Medicinal Chemistry CYLD-Mediated Signaling and Diseases
Current Drug Targets Blockade of MUC1 Expression by Glycerol Guaiacolate Inhibits Proliferation of Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathology and Molecular Markers of Ductal Carcinoma in-situ
Current Cancer Therapy Reviews Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Synthesis and Biological Evaluation of Triazole-Vanillin Molecular Hybrids as Anti-Cancer Agents
Current Bioactive Compounds Effect of Environmental Contaminants on Mammalian Testis
Current Molecular Pharmacology Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Insights on the Use of Nanocarriers for Acne Alleviation
Current Drug Delivery